BTG 511
Latest Information Update: 21 Aug 2019
At a glance
- Originator Unknown
- Developer BTG
- Class
- Mechanism of Action Bile acid binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 15 Mar 2004 This compound is still in active development - (BPN-2004)
- 14 Nov 2001 BTG 511 is available for licensing (http://www.btgplc.com)